Here's when you can get the FDA-approved, daily pill version of Novo Nordisk's wildly popular GLP-1 drug Wegovy.

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say.

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Appetite-suppressing GLP-1 tablets become accessible in January, and manufacturers and fast-food eateries may be pushed to alter more of their goods.

For the millions of Americans navigating the booming landscape of weight loss medications, the weekly injection routine just ...

Novo Nordisk's Wegovy pill is the first oral GLP-1 receptor agonist approved for weight management, offering a new treatment ...

Packaged food makers and fast-food chains are bracing for change as GLP-1 pills become available, following FDA approval of Novo Nordisk's Wegovy. The pills, expected to be cheaper than injections, ...